Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline-Reference-Cited by-同舟云学术

Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline

Published:2015-03 Issue:2 Volume:11 Page:135-136
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Rekhtman Natasha¹,Leighl Natasha B.¹,Somerfield Mark R.¹

Affiliation:

1. Memorial Sloan Kettering Cancer Center, New York, NY; Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and American Society of Clinical Oncology, Alexandria, VA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology (nursing),Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JOP.2014.002303

Reference2 articles.

1. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

2. Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discordant ALK Status in Non-Small Cell Lung Carcinoma: A Detailed Reevaluation Comparing IHC, FISH, and NGS Analyses;International Journal of Molecular Sciences;2024-07-26

2. Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece;Expert Review of Pharmacoeconomics & Outcomes Research;2023-11-24

3. Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non–Small-Cell Lung Cancer in the Netherlands;JCO Precision Oncology;2022-07

4. Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece;Journal of Health Economics and Outcomes Research;2022-02-17

5. Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer;Frontiers in Oncology;2021-05-28